Physician profile
Sasa Vukelic
NPI 1073741229
$8,012.23
in general payments reported to CMS, 2019-2025
27 companies · $3,369 in 2025
The $3,369 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $152 · 2021: $351 · 2022: $646 · 2023: $707 · 2024: $1,948 · 2025: $3,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,926 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,925.60 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,949.32 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $1,044.68 | 2024-2025 | Impella |
| Scpharmaceuticals INC. | $455.06 | 2023-2025 | |
| Cvrx, INC. | $361.59 | 2022-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $290.29 | 2022-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $233.15 | 2024-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $207.97 | 2023-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $194.81 | 2023-2024 | Livtencity |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Angiodynamics, INC. | $153.64 | 2025 | Alphavac |
| E.R. Squibb & Sons, L.L.C. | $151.62 | 2024-2025 | Camzyos, Eliquis |
| Recor Medical INC | $146.15 | 2025 | Paradise Ultrasound Renal Denervation System |
| Verona Pharma, INC. | $121.03 | 2025 | Ohtuvayre |
| Pfizer INC. | $104.64 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.21 | 2019-2025 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.61 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $65.04 | 2024-2025 | Wainua |
| Atricure, INC. | $27.97 | 2025 | Synergy Ablation System |
| Akcea Therapeutics, INC. | $25.82 | 2019 | |
| Novo Nordisk INC | $25.09 | 2024 | Wegovy |
| Veloxis Pharmaceuticals, INC. | $23.96 | 2024 | Envarsus |
| Philips North America LLC | $21.10 | 2022 | |
| Irhythm Technologies, INC. | $20.63 | 2023 | Zio Xt Patch |
| Boston Scientific Corporation | $20.56 | 2024 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $14.92 | 2024 | Arcalyst |
| Amgen INC. | $14.29 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasa Vukelic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.